A new clinical trial from drugmaker Eli Lilly shows that Zepbound and Mounjaro reduced obstructive sleep apnea symptoms. Tirzepatide, the main ingredient in these medications, reduced symptom severity by nearly two-thirds. Around 20% of participants taking tirzepatide experienced weight loss.

Related Keywords

New Jersey , United States , Hackensack , Germany , China , Brazil , Australia , Eli Lilly , Seth Kipnis , Mir Ali , Hackensack Meridian Jersey Shore University Medical Center , Aeroflow Sleep , Medical News , Memorialcare Surgical Weight Loss Center , Orange Coast Medical Center , Fountain Valley , Monique May ,